1stOncology™: Cancer Intelligence Service – Page 6116 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Adicet Bio to Present at Upcoming Investor Conferences

On August 1, 2022 Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, reported that company management will participate in three upcoming investor conferences in August (Press release, Adicet Bio, AUG 1, 2022, View Source [SID1234617221]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details of the events are as follows:

BTIG Biotech Conference, August 8-9, 2022

Chen Schor, President & CEO, will participate in a fireside chat at the conference on Monday, August 8, 2022.
Wedbush Pacgrow Healthcare Conference, August 9-10, 2022

Chen Schor, President & CEO, will participate in a virtual panel discussion titled, "A View to a Kill(er) Cell – Part 1" on Wednesday, August 10, 2022, at 1:10 P.M. ET.
Canaccord Genuity Annual Growth Conference, August 8-11, 2022, Boston, Massachusetts

Chen Schor, President & CEO, will present a corporate overview on Thursday, August 11, 2022, at 11:00 A.M. ET.
The live audio webcast of the Canaccord Genuity presentation and Wedbush panel can be accessed on the Investors section of Adicet Bio’s website at View Source An archived replay will be available for 30 days following the presentation.

Quanterix’ Second Quarter 2022 Earnings Conference Call

On August 1, 2022 Quanterix Corporation (NASDAQ: QTRX), a company expanding the limits of exploration with ultrasensitive biomarker detection, reported it will host a conference call on Monday, August 8, 2022, to discuss its second quarter 2022 financial results (Press release, Quanterix, AUG 1, 2022, View Source [SID1234617220]). The call will begin at 4:30 PM Eastern Time. It will be hosted by Masoud Toloue, the Company’s President and Chief Executive Officer, and Michael Doyle, the Company’s Chief Financial Officer.

Quanterix will issue a press release regarding the second quarter 2022 earnings prior to the conference call. The press release will be posted on the Company’s website at www.quanterix.com.

Please click here to pre-register for the conference call and obtain your dial in number and passcode. You can also visit this link to listen to the call via live webcast. You may also access the live webcast by visiting the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. The webcast will be available on the Company’s website for one year following completion of the call.

Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

On August 1, 2022 Cyteir Therapeutics, Inc. ("Cyteir") (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, reported that its President and Chief Executive Officer, Markus Renschler, MD, will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022 (Press release, Cyteir Therapeutics, AUG 1, 2022, View Source [SID1234617219]).

2022 Wedbush PacGrow Healthcare Conference
Date: Tuesday, August 9
Time: 12:00 PM EDT
Panel: Synthetic Lethal (Weapon) – Part 1

A live webcast of the Wedbush panel discussion will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

On August 1, 2022 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, reported that it will prioritize NUV-868 and development of its novel small molecule DDC platform and discontinue clinical development of NUV-422 (Press release, Nuvation Bio, AUG 1, 2022, View Source [SID1234617218]).

The decision to discontinue clinical development of NUV-422 is the result of an internal risk-benefit analysis factoring in feedback received from the U.S. Food and Drug Administration (FDA) in a partial clinical hold letter for the Company’s monotherapy Phase 1/2 study (Protocol NUV-422-02) and clinical hold letters for its combination Phase 1b/2 studies (Protocols NUV-422-03 and NUV-422-04). The FDA verbally placed a partial clinical hold on the Phase 1 dose escalation portion of the Company’s NUV-422-02 study in June 2022. At that time, the Company had proactively paused enrollment of new patients following the emergence of a safety signal, uveitis, which is a form of inflammation of the eye. Furthermore, the FDA requested a mitigation plan to address the adverse event of uveitis. Given that the etiology of uveitis associated with NUV-422 is not understood and that its development appears unpredictable, the Company believes that it would be difficult to craft an effective mitigation plan without significant further research.

Nuvation Bio will intensify its focus and concentrate its resources on the clinical development of NUV-868, its BD2-selective BET inhibitor, and identifying a lead clinical candidate from its novel small molecule DDC platform. Enrollment is ongoing in the Phase 1 monotherapy study of NUV-868, and the Company has planned Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide to enhance the potential value of this program across multiple tumor types.

A reduction in work force of 35% and other cost savings associated with the NUV-422 program discontinuation will enable Nuvation Bio to extend its cash runway through 2028. The Company expects to report a balance of approximately $703.8 million in cash, cash equivalents and marketable securities as of June 30, 2022.

"Nuvation Bio was founded on a commitment to advance a broad pipeline of innovative therapies as quickly and safely as possible for people with cancers that do not currently have adequate treatment options. As part of this commitment, we have always operated as a scientifically rigorous, data-driven company. Following an extensive analysis of the Phase 1 dose escalation study of NUV-422 in solid tumors, we made the determination that uveitis cannot be safely managed. We sincerely thank all patients and investigators who were part of the NUV-422 clinical program for their prodigious efforts. We also thank our employees for their commitment to the Nuvation Bio mission. It was a difficult decision to discontinue the program and we are extremely grateful for each of their contributions," said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.

Dr. Hung added: "We believe that our disciplined, data-driven and timely decision to prioritize our other programs over the NUV-422 program based on our most recent clinical data serves to increase our probability of ultimate success in our efforts to bring game-changing drugs to patients who desperately need them. To that end, we are excited to continue enrolling patients in the NUV-868 Phase 1 study and are encouraged by our progress with our novel small molecule DDC platform. With a robust cash balance and a world class drug development team, we are well positioned to progress these priority programs in some of the most difficult-to-treat cancers."

AnHeart Therapeutics Appoints Dr. Shuanglian (Lian) Li as Chief Medical Officer (US)

On August 1, 2022 AnHeart Therapeutics ("AnHeart"), a clinical-stage global biopharmaceutical company committed to developing novel precision oncology therapeutics, reported the appointment of Shuanglian (Lian) Li, M.D., Ph.D., as the company’s Senior Vice President and Chief Medical Officer (US) (Press release, AnHeart Therapeutics, AUG 1, 2022, View Source [SID1234617217]). In this role, Dr. Li will oversee and direct all U.S.-based clinical programs.

Dr. Li is an accomplished clinical development physician with over 15 years of drug development experience from preclinical drug safety to late-stage drug development and post-marketing clinical research. Her clinical development expertise has specialized in precision medicine and adoptive cellular therapy.

Prior to joining AnHeart, Dr. Li was SVP, Clinical Development at Ansun Biopharma, where she led and drove the overall clinical development strategy of the company’s oncology pipeline and clinical development plan. She also led clinical and regulatory strategy as Head of Clinical Development at Skyline Therapeutics, a gene therapy company headquartered in Shanghai.

Dr. Li was also the Global Clinical Lead for mobocertinib, a first-in-class EGFR inhibitor that targeted EGFR exon 20 insertions, at Takeda Pharmaceuticals. Prior to its acquisition by Takeda, Dr. Li was Medical Director at ARIAD Pharmaceuticals and the medical lead for several oncology programs. Dr. Li has held various positions with increasing responsibilities at Biogen, Pfizer and Sugen.

"We’re delighted to welcome Dr. Li to AnHeart Therapeutics. She brings more than 15 years of experience leading high-performing teams in clinical development, and has a proven track record of success with multiple FDA approvals in oncology," said Junyuan (Jerry) Wang, Ph.D. CEO & Co-Founder, AnHeart Therapeutics. "Dr. Li is precisely the type of high-quality individual we are recruiting as we grow our company. She will be an invaluable asset to AnHeart and our leadership team as we advance our clinical pipeline focused on ROS1-directed therapeutics."

"I am excited to join AnHeart at such a dynamic time. The company is developing multiple cancer therapies including lead asset taletrectinib targeting ROS1-fusion and resistant mutations. AnHeart’s mission to transform the lives of cancer patients with breakthrough medicines and exciting programs attracted me to the role, and I look forward to working with the management and scientific teams to bring innovative therapies to cancer patients," said Dr. Li.

Dr. Li received her Ph.D. in Pharmaceutical Sciences & Pharmacogenomics, from the University of California, San Francisco and an M.D. from Beijing Medical University. She also obtained an M.S. in Pharmacology & Toxicology from the University of Mississippi.